18 March 2021 | News
The collaboration includes the distribution of the GenScript cPass™ SARS-CoV-2 Neutralization Antibody Detection Kit across 24 geographies in the MENA region
GenScript Biotech Singapore, a subsidiary of GenScript Biotech Corporation, a world leading biotechnology company and G42 Healthcare, a leading healthcare technology company, based in the UAE, have announced that they have signed an agreement to explore comprehensive solutions to fight COVID-19.
The collaboration includes the distribution of the GenScript cPass™ SARS-CoV-2 Neutralization Antibody Detection Kit across 24 geographies in the MENA region to assess vaccine effectiveness.
The GenScript cPass™ SARS-CoV-2 Neutralization Antibody Detection Kitdetects neutralizing antibodies in individuals without the use of the live virus. The conventional method of measuring neutralizing antibodies in patient samples requires the use of live cells and a high biosafety level environment (BSL3). Obtaining results also takes multiple days.
In contrast, the cPass™ kit utilizes pure proteins and can be performed in most standard laboratories with a short turnaround time (~1hr). Neutralizing antibodies represent the first line of defense against SARS CoV-2 infection by blocking the virus from binding to the host cells, thus inhibiting viral propagation.
The cPass™ test may be an essential tool for the detection ofthe neutralizing (virus blocking) antibody response at post-vaccination to understand the robustness, efficacy, and longevity of the immune response.
The cPass™ kit is the only U.S. FDA Emergency Use Authorized serology test for neutralizing antibodies from recent and prior SARS-CoV-2 infections. The kit is also CE marked (Europe) and has received HSA provisional approval (Singapore), ANVISA in Brazil, ANMAT in Argentina and has recently received clearance from the Ministry of Health and Prevention (MOHAP) in the UAE as a medical device.
"We are glad to be working with G42 Healthcare and contribute to the development of innovative solutions to help the people of the UAE and beyond. With this collaboration, we will join forces to serve the local community with our expertise and resources. Our company remains committed to supporting the healthcare community in combatting COVID-19 infections, with a broad portfolio of research and development tools and diagnostics, including the novel cPass kit." said Johnson Wang, Asia Pacific President of GenScript.